194 related articles for article (PubMed ID: 10645890)
21. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease.
Schmid M; Fellermann K; Fritz P; Wiedow O; Stange EF; Wehkamp J
J Leukoc Biol; 2007 Apr; 81(4):907-15. PubMed ID: 17200145
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of alpha- and beta-defensin on cytokine production by cultured human bronchial epithelial cells.
Sakamoto N; Mukae H; Fujii T; Ishii H; Yoshioka S; Kakugawa T; Sugiyama K; Mizuta Y; Kadota J; Nakazato M; Kohno S
Am J Physiol Lung Cell Mol Physiol; 2005 Mar; 288(3):L508-13. PubMed ID: 15557089
[TBL] [Abstract][Full Text] [Related]
23. DNA from bronchial secretions modulates elastase inhibition by alpha(1)-proteinase inhibitor and oxidized secretory leukoprotease inhibitor.
Ying QL; Simon SR
Am J Respir Cell Mol Biol; 2000 Oct; 23(4):506-13. PubMed ID: 11017916
[TBL] [Abstract][Full Text] [Related]
24. Expression of the secretory leukoprotease inhibitor gene in epithelial cells.
Abe T; Kobayashi N; Yoshimura K; Trapnell BC; Kim H; Hubbard RC; Brewer MT; Thompson RC; Crystal RG
J Clin Invest; 1991 Jun; 87(6):2207-15. PubMed ID: 1674946
[TBL] [Abstract][Full Text] [Related]
25. Analysis of secretory leukocyte protease inhibitor (SLPI) in bronchial secretions from patients with hypersecretory respiratory diseases.
Kouchi I; Yasuoka S; Ueda Y; Ogura T
Tokushima J Exp Med; 1993 Jun; 40(1-2):95-107. PubMed ID: 8105562
[TBL] [Abstract][Full Text] [Related]
26. Regulation of the secretory phenotype of human airway epithelium by retinoic acid, triiodothyronine, and extracellular matrix.
Yoon JH; Gray T; Guzman K; Koo JS; Nettesheim P
Am J Respir Cell Mol Biol; 1997 Jun; 16(6):724-31. PubMed ID: 9191474
[TBL] [Abstract][Full Text] [Related]
27. SLPI and elafin: one glove, many fingers.
Williams SE; Brown TI; Roghanian A; Sallenave JM
Clin Sci (Lond); 2006 Jan; 110(1):21-35. PubMed ID: 16336202
[TBL] [Abstract][Full Text] [Related]
28. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.
Vogelmeier C; Hubbard RC; Fells GA; Schnebli HP; Thompson RC; Fritz H; Crystal RG
J Clin Invest; 1991 Feb; 87(2):482-8. PubMed ID: 1671391
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium.
Hiemstra PS; van Wetering S; Stolk J
Eur Respir J; 1998 Nov; 12(5):1200-8. PubMed ID: 9864022
[TBL] [Abstract][Full Text] [Related]
30. Secretory leukoprotease inhibitor augments hepatocyte growth factor production in human lung fibroblasts.
Kikuchi T; Abe T; Yaekashiwa M; Tominaga Y; Mitsuhashi H; Satoh K; Nakamura T; Nukiwa T
Am J Respir Cell Mol Biol; 2000 Sep; 23(3):364-70. PubMed ID: 10970828
[TBL] [Abstract][Full Text] [Related]
31. Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor.
Mihaila A; Tremblay GM
Z Naturforsch C J Biosci; 2001; 56(3-4):291-7. PubMed ID: 11371023
[TBL] [Abstract][Full Text] [Related]
32. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.
Zani ML; Baranger K; Guyot N; Dallet-Choisy S; Moreau T
Protein Sci; 2009 Mar; 18(3):579-94. PubMed ID: 19241385
[TBL] [Abstract][Full Text] [Related]
33. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells.
Abbinante-Nissen JM; Simpson LG; Leikauf GD
Am J Physiol; 1995 Apr; 268(4 Pt 1):L601-6. PubMed ID: 7733301
[TBL] [Abstract][Full Text] [Related]
34. The inhibitory effect of secretory leukocyte protease inhibitor (SLPI) on formation of neutrophil extracellular traps.
Zabieglo K; Majewski P; Majchrzak-Gorecka M; Wlodarczyk A; Grygier B; Zegar A; Kapinska-Mrowiecka M; Naskalska A; Pyrc K; Dubin A; Wahl SM; Cichy J
J Leukoc Biol; 2015 Jul; 98(1):99-106. PubMed ID: 25917460
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of secretory leukocyte proteinase inhibitor in chronic obstructive lung disease: the role of TGF-beta/Smads signaling pathways.
Luo BL; Niu RC; Feng JT; Hu CP; Xie XY; Ma LJ
Arch Med Res; 2008 May; 39(4):388-96. PubMed ID: 18375249
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial activity of antiproteinases.
Sallenave JM
Biochem Soc Trans; 2002 Apr; 30(2):111-5. PubMed ID: 12023836
[TBL] [Abstract][Full Text] [Related]
37. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis.
Birrer P; McElvaney NG; Rüdeberg A; Sommer CW; Liechti-Gallati S; Kraemer R; Hubbard R; Crystal RG
Am J Respir Crit Care Med; 1994 Jul; 150(1):207-13. PubMed ID: 7912987
[TBL] [Abstract][Full Text] [Related]
38. Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome.
Sallenave JM; Donnelly SC; Grant IS; Robertson C; Gauldie J; Haslett C
Eur Respir J; 1999 May; 13(5):1029-36. PubMed ID: 10414400
[TBL] [Abstract][Full Text] [Related]
39. Secretory leukocyte proteinase inhibitor, alpha-1-antitrypsin deficiency and emphysema: Preliminary study, speculation and an hypothesis.
Ayad MS; Knight KR; Burdon JG; Brenton S
Respirology; 2003 Jun; 8(2):175-80. PubMed ID: 12753532
[TBL] [Abstract][Full Text] [Related]
40. Interaction of secretory leukocyte protease inhibitor with proteinase-3.
Rao NV; Marshall BC; Gray BH; Hoidal JR
Am J Respir Cell Mol Biol; 1993 Jun; 8(6):612-6. PubMed ID: 8100709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
